• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Mammography Study: Paying for Adjunctive AI Screening Led to 43 Percent Higher Rate of Breast Cancer Detection

News
Article

In a multicenter study involving over 747,000 women who had mammography screening, those who paid for AI-enhanced screening had a 21 percent higher recall rate and a 15 percent higher positive predictive value (PPV) for breast cancer, according to research presented at the Radiological Society of North America (RSNA) conference.

Emerging multicenter research suggests that over one-third of women are willing to pay for artificial intelligence (AI)-enhanced mammography screening and had a 43 percent higher average cancer detection rate (CDR) than those who did not have adjunctive AI screening.

For the multicenter study, presented at the Radiological Society of North America (RSNA) conference, researchers reviewed mammography screening data from 747,604 women and compared the CDR, recall rate and positive predictive value (PPV) for women who opted to self-pay for AI-enhanced screening and those who did not.

At one year, the researchers found that women who had adjunctive AI screening had a 43 percent higher CDR (5.95 vs. 4.15 per 1000). The study authors noted that the use of adjunctive AI accounted for 21 percent of the increased CDR and maintained that 22 percent of the increased CDR was due to patients at higher risk for breast cancer enrolling more frequently for adjunctive AI screening.

Mammography Study: Paying for Adjunctive AI Screening Led to 43 Percent Higher Rate of Breast Cancer Detection

In a multicenter study evaluating patient self-pay for the use of adjunctive AI in mammography screening, researchers found that adjunctive AI led to a 43 percent higher cancer detection rate, a 21 percent higher recall rate and a 15 percent higher positive predictive value in comparison to women who did not have adjunctive AI.

“These data indicate that many women are eager to utilize AI to enhance their screening mammogram, and when AI is coupled with a safeguard review, more cancers are found,” noted Gregory Sorensen, M.D., a senior author of the study and chief executive officer of DeepHealth.

The use of adjunctive AI yielded a 21 percent higher recall rate (10.9 percent vs. 8.8 percent) but also led to a 15 percent higher PPV (5.4 percent vs. 4.6 percent), according to the study authors.

(Editor’s note: For additional coverage from the RSNA conference, click here.)

“The AI-driven enhanced review program leverages AI in a novel workflow to ensure women with suspicious findings get expert level care that could help detect many more breast cancers early,” emphasized Bryan Haslam, Ph.D., a co-author of the study and chief product officer at DeepHealth. “The number of women electing for this program is now at 36% and growing, and the rate of cancer detection continues to be substantially higher for those women.”

Reference

1. Sorensen AG, Haslam B, Louis L, Holt JS, Storella JM. Patient self-pay for AI-driven enhanced review program in screening mammography: initial experience. Poster presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .

Recent Videos
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.